Sermorelin Before and After: What Studies Found vs What Photos Show
Online galleries promise transformations. The published studies measured something much smaller.
Words by the editors ·
There is no controlled before-and-after evidence for sermorelin in healthy men, and the photo galleries online are not evidence. What the published studies measured is narrower: a rise in growth hormone and IGF-1 in the blood, a small gain in lean mass in one trial of older people (men only), and no change in muscle or fat in another.23 Below is each finding, how big the study was, and why a "before and after" claim goes further than the data.
In brief
- We found no controlled trial of sermorelin tracking body composition, skin or energy in healthy adult men, and a 2026 review calls the physique benefits sold online uncertain.1
- In a placebo-controlled trial of a modified GHRH analog in 19 people aged 55 to 71, lean body mass rose in men only, with no other body composition change.2
- In 11 healthy men aged 64 to 76, six weeks of nightly GHRH raised nighttime growth hormone but did not change DEXA muscle or fat.3
- In a 14-man chart review, IGF-1 rose from 159.5 to 239.0 ng/mL, but sermorelin was combined with two other peptides and there was no control group.4
Is there any real before and after evidence for sermorelin?
Not in the form searchers imagine. We found no trial that photographed or tracked healthy adult men on sermorelin against a placebo group for body composition, skin, sleep or energy. The 2026 review of growth hormone axis peptides sorts them by evidence tier, and describes the benefits sold for physique and recomposition as uncertain, because human data are limited and products sold online vary in composition and dose.1 Sermorelin itself has a DailyMed absence worth knowing: a search on October 24, 2026 listed no sermorelin label, so adults who use it receive a compounded product, which the FDA says is not FDA-approved.56
What are the results of sermorelin?
The measured results are small and mostly in blood tests: higher growth hormone and IGF-1 levels, with a modest lean mass gain in men in one trial of an analog and no change in DEXA muscle or fat in another.23 In children with growth hormone deficiency, sermorelin was studied for height growth, a different goal from physique in adult men.7 We found no controlled trial showing visible change in healthy adults, so any promised result goes beyond the published data.1
What did the studies actually measure?
| Study | Who and how long | What changed | What did not |
|---|---|---|---|
| Review of sermorelin in children with growth hormone deficiency7 | Prepubertal children; 30 mcg/kg at bedtime | Height velocity rose and was sustained over 12 months in some children | Not adults; says nothing on muscle or skin in men |
| Placebo-controlled trial of a modified GHRH analog2 | 9 men and 10 women aged 55 to 71; 4 weeks placebo, then 16 weeks nightly | Growth hormone and IGF-1 rose; skin thickness rose in both sexes; lean body mass rose in men only | No other body composition or bone density change; an analog, not sermorelin itself |
| Trial of nightly GHRH 1-293 | 11 healthy men aged 64 to 76; 6 weeks | Nighttime growth hormone release rose; 2 of 6 strength measures and one endurance test improved | IGF-1, weight, DEXA muscle and fat did not change |
| Retrospective chart review4 | 14 of 105 men on testosterone therapy who met compliance rules; average age 33; 134 days | IGF-1 rose from 159.5 to 239.0 ng/mL | Combined sermorelin with GHRP-2 and GHRP-6, no control group, no body composition outcome |
What do these results mean for body composition?
Very little can be promised. In the 19-person analog trial, lean body mass rose in men but not in women, and fat mass, bone density and body weight did not change.2 In the 11-man trial, six weeks of nightly injections did not change DEXA measures of muscle or fat.3 A blood marker moving, as in the 14-man chart review, is not the same as a visible change: the authors used IGF-1 as a stand-in for growth hormone and suggested the combination might help men with wasting conditions, not that it changes appearance.4
The chart review also matters for what it combined. Those men took sermorelin together with two other peptides, three times a day, so the rise cannot be credited to sermorelin alone.4
What about skin, sleep and energy?
Skin thickness did increase in the analog trial, in both sexes, measured by calipers; that is a measurement, not a cosmetic result.2 The same trial found improved general well-being and libido in men, and no change in sleep quality in either sex, using self-completed questionnaires in a small, single-blind study.2 We found no trial of sermorelin that tested energy or recovery against placebo. Claims of visible change "around week 12" on commercial pages cite no study we could load.
What about sermorelin for females, before and after?
There is even less evidence for women than for men. In the placebo-controlled analog trial, 10 women took part alongside 9 men; skin thickness rose in both sexes, but lean body mass rose in men only, and fat mass and bone density did not change.2 A separate randomized study in healthy young women found that intravenous GHRH raised growth hormone but decreased REM sleep at one dose and sleep stage 4 at another, and the authors concluded systemic GHRH impairs sleep in women.8 That was a hormone given by vein in a sleep lab, not compounded sermorelin injections, so it does not show what a home protocol does. We found no trial tracking appearance in women on sermorelin.
Is there hexarelin or growth hormone peptide before and after evidence?
Not in humans that we could find. Searching PubMed for hexarelin in the title returned recent studies in rats, mice and cell lines, such as protection against kidney injury in rats and lung injury in mice, not body composition in people.910 Animal findings do not show that a peptide changes appearance in people. For the wider class of growth hormone peptides, the 2026 review of this axis describes physique benefits as uncertain, and the human trials we cite above used GHRH or an analog, not hexarelin.1
Why do before and after photos mislead?
- No comparison group. A man who also changes diet, lifting and sleep will look different with or without a peptide.
- Selected cases. Photos are chosen, not sampled. In the chart review, only 14 of 105 men met the compliance rules.4
- Mixed products. Many programs use several peptides at once, and the 2026 review notes uncertain composition, dose and stacking in unregulated supply chains.1
- Lighting and posing. A photo cannot show IGF-1, glucose or blood fats, the things studies did measure.
What should a man ask instead?
- Which measurable outcome is being tracked, such as IGF-1, glucose, lipids and body composition, and when is it reviewed?
- Which study supports the dose, and in what population was it done? Published doses are in our review of sermorelin dosing in the studies.
- What are the known downsides? Flushing, injection-site pain and possible blood fat or glucose changes are covered in what studies report on side effects.
- Who compounds it, and how is it labeled?
For the wider question of whether the benefits sold are supported, read whether sermorelin is worth it, and for the basics, what sermorelin is.
Bottom line
The honest "after" is a blood marker, sometimes a small change in lean mass or skin thickness, in small and short studies, mostly in older people or with other peptides. No study shows the transformations shown online. A man considering it should weigh that gap, and a clinician who knows his history should make the call.
Questions
Does sermorelin really change how you look?
We found no controlled trial showing visible change in healthy men. Small studies measured hormone levels, and in one trial a small lean mass gain in men only.
How long does sermorelin take to show results?
No trial we loaded sets a timeline for visible change. The studies ran 6 weeks to 5 months and measured blood markers and body composition scans, not appearance.
Are sermorelin before and after photos real evidence?
No. Photos lack a comparison group, are selected, and often reflect diet and training changes or several peptides taken together.
Is sermorelin FDA-approved?
A DailyMed search on October 24, 2026 listed no sermorelin label. Compounded drugs are not FDA-approved, per the FDA.
What are the results of sermorelin?
Studies measured higher growth hormone and IGF-1, a small lean mass gain in men in one analog trial and no muscle or fat change in another. No controlled trial shows visible change in healthy adults.
Is there sermorelin before and after evidence for women?
We found none. One analog trial had 10 women and showed thicker skin but no lean mass gain, and a lab study found GHRH impaired sleep in young women.
Also in this edition
Part of our guide: Sermorelin: The Complete Guide
Notes
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026. PubMed 42395176.
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997. PubMed 9141536.
- Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997. PubMed 9005976.
- Sigalos JT, et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017. PubMed 28830317.
- Sermorelin search. DailyMed, U.S. National Library of Medicine. Searched October 24, 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173.
- Mathias S, et al. Systemic growth hormone-releasing hormone (GHRH) impairs sleep in healthy young women. Psychoneuroendocrinology. 2007. PubMed 17850984.
- Guan C, et al. Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. Eur J Med Res. 2023. PubMed 37710348.
- Celikoglu O, et al. Protective and restorative effects of hexarelin on MPTP-induced lung injury in mice. J Basic Clin Physiol Pharmacol. 2026. PubMed 42619489.